Literature DB >> 6177437

Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.

A T Look, G V Dahl, G Rivera, A M Mauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6177437     DOI： 10.1007/BF00254540

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  14 in total

Review 1.  Advances in the treatment of acute myelogenous leukemia.

Authors:  R P Gale
Journal:  N Engl J Med       Date:  1979-05-24       Impact factor: 91.245

2.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.

Authors:  G Mathé; L Schwarzenberg; P Pouillart; R Oldham; R Weiner; C Jasmin; C Rosenfeld; M Hayat; J L Misset; M Musset; M Schneider; J L Amiel; F De Vassal
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  5-Azacytidine: a new active agent for the treatment of acute leukemia.

Authors:  M Karon; L Sieger; S Leimbrock; J Z Finklestein; M E Nesbit; J J Swaney
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

4.  5-azacytidine in acute leukemia.

Authors:  J H Saiki; K B McCredie; T J Vietti; J S Hewlett; F S Morrison; J J Costanzi; W J Stuckey; J Whitecar; B Hoogstraten
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

5.  A simplified method of DNA distribution analysis.

Authors:  P N Dean
Journal:  Cell Tissue Kinet       Date:  1980-05

6.  Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

Authors:  B Drewinko; B Barlogie
Journal:  Cancer Treat Rep       Date:  1976-09

7.  Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.

Authors:  A T Look; G V Dahl; D Kalwinsky; N Senzer; C Mason; G Rivera
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Treatment of acute myelogenous leukemia in children and adults.

Authors:  H J Weinstein; R J Mayer; D S Rosenthal; B M Camitta; F S Coral; D G Nathan; E Frei
Journal:  N Engl J Med       Date:  1980-08-28       Impact factor: 91.245

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539
View more
  4 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.

Authors:  E Erba; P Ubezio; T Colombo; M Broggini; L Torti; M Vaghi; M D'Incalci; L Morasca
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.